442 related articles for article (PubMed ID: 29338538)
21. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin.
Barrett FS; Johnson MW; Griffiths RR
J Psychopharmacol; 2015 Nov; 29(11):1182-90. PubMed ID: 26442957
[TBL] [Abstract][Full Text] [Related]
22. The hidden therapist: evidence for a central role of music in psychedelic therapy.
Kaelen M; Giribaldi B; Raine J; Evans L; Timmerman C; Rodriguez N; Roseman L; Feilding A; Nutt D; Carhart-Harris R
Psychopharmacology (Berl); 2018 Feb; 235(2):505-519. PubMed ID: 29396616
[TBL] [Abstract][Full Text] [Related]
23. Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder.
Schneier FR; Feusner J; Wheaton MG; Gomez GJ; Cornejo G; Naraindas AM; Hellerstein DJ
J Psychiatr Res; 2023 May; 161():364-370. PubMed ID: 37004409
[TBL] [Abstract][Full Text] [Related]
24. Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression.
Carrillo F; Sigman M; Fernández Slezak D; Ashton P; Fitzgerald L; Stroud J; Nutt DJ; Carhart-Harris RL
J Affect Disord; 2018 Apr; 230():84-86. PubMed ID: 29407543
[TBL] [Abstract][Full Text] [Related]
25. The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation.
Rucker JJ; Marwood L; Ajantaival RJ; Bird C; Eriksson H; Harrison J; Lennard-Jones M; Mistry S; Saldarini F; Stansfield S; Tai SJ; Williams S; Weston N; Malievskaia E; Young AH
J Psychopharmacol; 2022 Jan; 36(1):114-125. PubMed ID: 35090363
[TBL] [Abstract][Full Text] [Related]
26. More Realistic Forecasting of Future Life Events After Psilocybin for Treatment-Resistant Depression.
Lyons T; Carhart-Harris RL
Front Psychol; 2018; 9():1721. PubMed ID: 30369890
[No Abstract] [Full Text] [Related]
27. Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study.
Marschall J; Fejer G; Lempe P; Prochazkova L; Kuchar M; Hajkova K; van Elk M
J Psychopharmacol; 2022 Jan; 36(1):97-113. PubMed ID: 34915762
[TBL] [Abstract][Full Text] [Related]
28. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.
Grob CS; Danforth AL; Chopra GS; Hagerty M; McKay CR; Halberstadt AL; Greer GR
Arch Gen Psychiatry; 2011 Jan; 68(1):71-8. PubMed ID: 20819978
[TBL] [Abstract][Full Text] [Related]
29. Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history.
Pearson C; Siegel J; Gold JA
J Neurol Sci; 2022 Mar; 434():120096. PubMed ID: 34942586
[TBL] [Abstract][Full Text] [Related]
30. Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders.
Wulff AB; Nichols CD; Thompson SM
Neuropharmacology; 2023 Jun; 231():109504. PubMed ID: 36921889
[TBL] [Abstract][Full Text] [Related]
31. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later.
Griffiths R; Richards W; Johnson M; McCann U; Jesse R
J Psychopharmacol; 2008 Aug; 22(6):621-32. PubMed ID: 18593735
[TBL] [Abstract][Full Text] [Related]
32. Psilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach.
Agin-Liebes G; Davis AK
Curr Top Behav Neurosci; 2022; 56():125-140. PubMed ID: 34811715
[TBL] [Abstract][Full Text] [Related]
33. Psychedelics and the 'inner healer': Myth or mechanism?
Peill J; Marguilho M; Erritzoe D; Barba T; Greenway KT; Rosas F; Timmermann C; Carhart-Harris R
J Psychopharmacol; 2024 May; 38(5):417-424. PubMed ID: 38605658
[TBL] [Abstract][Full Text] [Related]
34. Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study.
Breeksema JJ; Niemeijer A; Krediet E; Karsten T; Kamphuis J; Vermetten E; van den Brink W; Schoevers R
Sci Rep; 2024 Feb; 14(1):2929. PubMed ID: 38316896
[TBL] [Abstract][Full Text] [Related]
35. Psychedelics, With a Focus on Psilocybin: Issues for the Clinician.
Garakani A; Alexander JL; Sumner CR; Pine JH; Gross LS; Raison CL; Aaronson ST; Baron DA
J Psychiatr Pract; 2023 Sep; 29(5):345-353. PubMed ID: 37678363
[TBL] [Abstract][Full Text] [Related]
36. Assessing potential of psilocybin for depressive disorders.
Kozak Z; Johnson MW; Aaronson ST
Expert Opin Investig Drugs; 2023; 32(10):887-900. PubMed ID: 37869790
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression.
Mertens LJ; Wall MB; Roseman L; Demetriou L; Nutt DJ; Carhart-Harris RL
J Psychopharmacol; 2020 Feb; 34(2):167-180. PubMed ID: 31941394
[TBL] [Abstract][Full Text] [Related]
38. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences.
Carbonaro TM; Johnson MW; Hurwitz E; Griffiths RR
Psychopharmacology (Berl); 2018 Feb; 235(2):521-534. PubMed ID: 29116367
[TBL] [Abstract][Full Text] [Related]
39. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies.
Studerus E; Kometer M; Hasler F; Vollenweider FX
J Psychopharmacol; 2011 Nov; 25(11):1434-52. PubMed ID: 20855349
[TBL] [Abstract][Full Text] [Related]
40. The administration of psilocybin to healthy, hallucinogen-experienced volunteers in a mock-functional magnetic resonance imaging environment: a preliminary investigation of tolerability.
Carhart-Harris RL; Williams TM; Sessa B; Tyacke RJ; Rich AS; Feilding A; Nutt DJ
J Psychopharmacol; 2011 Nov; 25(11):1562-7. PubMed ID: 20395317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
